General information about company |
|||
|---|---|---|---|
| Scrip Code | 524470 | ||
| NSE Symbol | SYNCOMF | ||
| MSEI Symbol | NOTLISTED | ||
| ISIN | INE312C01025 | ||
| Name of company | SYNCOM FORMULATIONS (INDIA) LIMITED | ||
| Type of company | Main Board | ||
| Class of security | Equity | ||
| Date of start of financial year | 01-Apr-2025 | ||
| Date of end of financial year | 31-Mar-2026 | ||
| Date of board meeting when results were approved | 08-Aug-2025 | ||
| Date on which prior intimation of the meeting for considering financial results was informed to the exchange | 02-Aug-2025 | ||
| Description of presentation currency | INR (in Actuals) | ||
| Reporting Type | Quarterly | ||
| Reporting Quarter | First quarter | ||
| Nature of report standalone or consolidated | Consolidated | ||
| Whether results are audited or unaudited for the quarter ended | Unaudited | ||
| Whether results are audited or unaudited for the Year to date for current period ended/year ended | |||
| Segment Reporting | Multi segment | ||
| Description of single segment | |||
| Start date and time of board meeting | 08-Aug-2025 16:00:00 | ||
| End date and time of board meeting | 08-Aug-2025 16:45:00 | ||
| Whether cash flow statement is applicable on company | |||
| Type of cash flow statement | |||
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion | ||
Financial Results Ind-AS |
|||
|---|---|---|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
| A | Date of start of reporting period | 01-Apr-2025 | |
| B | Date of end of reporting period | 30-Jun-2025 | |
| C | Whether results are audited or unaudited | Unaudited | |
| D | Nature of report standalone or consolidated | Consolidated | |
| Part I | Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column. | ||
| 1 | Income | ||
| Revenue from operations | 1169017000 | ||
| Other income | 60347000 | ||
| Total income | 1229364000 | ||
| 2 | Expenses | ||
| (a) | Cost of materials consumed | 596130000 | |
| (b) | Purchases of stock-in-trade | 156813000 | |
| (c) | Changes in inventories of finished goods, work-in-progress and stock-in-trade | -61248000 | |
| (d) | Employee benefit expense | 159544000 | |
| (e) | Finance costs | 2508000 | |
| (f) | Depreciation, depletion and amortisation expense | 13400000 | |
| (f) | Other Expenses | ||
| 1 | Other Expenses | 159706000 | 159706000 |
| Total other expenses | 159706000 | ||
| Total expenses | 1026853000 | ||
| 3 | Total profit before exceptional items and tax | 202511000 | |
| 4 | Exceptional items | 413000 | |
| 5 | Total profit before tax | 202924000 | |
| 6 | Tax expense | ||
| 7 | Current tax | 43250000 | |
| 8 | Deferred tax | 2130000 | |
| 9 | Total tax expenses | 45380000 | |
| 10 | Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement | 0 | |
| 11 | Net Profit Loss for the period from continuing operations | 157544000 | |
| 12 | Profit (loss) from discontinued operations before tax | 0 | |
| 13 | Tax expense of discontinued operations | 0 | |
| 14 | Net profit (loss) from discontinued operation after tax | 0 | |
| 15 | Share of profit (loss) of associates and joint ventures accounted for using equity method | 0 | |
| 16 | Total profit (loss) for period | 157544000 | |
| 17 | Other comprehensive income net of taxes | 40384000 | |
| 18 | Total Comprehensive Income for the period | 197928000 | |
| 19 | Total profit or loss, attributable to | ||
| Profit or loss, attributable to owners of parent | |||
| Total profit or loss, attributable to non-controlling interests | |||
| 20 | Total Comprehensive income for the period attributable to | ||
| Comprehensive income for the period attributable to owners of parent | |||
| Total comprehensive income for the period attributable to owners of parent non-controlling interests | |||
| 21 | Details of equity share capital | ||
| Paid-up equity share capital | 940000000 | ||
| Face value of equity share capital | 1 | ||
| 27 | Details of debt securities | ||
| 22 | Reserves excluding revaluation reserve | ||
| 23 | Earnings per share | ||
| i | Earnings per equity share for continuing operations | ||
| Basic earnings (loss) per share from continuing operations | 0.21 | ||
| Diluted earnings (loss) per share from continuing operations | 0.21 | ||
| ii | Earnings per equity share for discontinued operations | ||
| Basic earnings (loss) per share from discontinued operations | 0 | ||
| Diluted earnings (loss) per share from discontinued operations | 0 | ||
| ii | Earnings per equity share | ||
| Basic earnings (loss) per share from continuing and discontinued operations | 0.21 | ||
| Diluted earnings (loss) per share from continuing and discontinued operations | 0.21 | ||
| 24 | Debt equity ratio | 0 | |
| 25 | Debt service coverage ratio | 0 | |
| 26 | Interest service coverage ratio | 0 | |
| 27 | Disclosure of notes on financial results | ||
Remarks |
|
|---|---|
| Debt equity ratio | |
| Debt service coverage ratio | |
| Interest service coverage ratio | |
Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results |
|||||||
|---|---|---|---|---|---|---|---|
| Particulars | 3 months/ 6 month ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |||||
| Date of start of reporting period | 01-Apr-2025 | ||||||
| Date of end of reporting period | 30-Jun-2025 | ||||||
| Whether accounts are audited or unaudited | Unaudited | ||||||
| Nature of report standalone or consolidated | Consolidated | ||||||
| 1 | Segment Revenue (Income) | ||||||
| (net sale/income from each segment should be disclosed) | |||||||
| 1 | Pharmaceuticals Drugs and Formulations | 1209995000 | 1209995000 | ||||
| 2 | Trading of Commodities | 10456000 | 10456000 | ||||
| 3 | Renting of Properties | 8913000 | 8913000 | ||||
| Total Segment Revenue | 1229364000 | ||||||
| Less: Inter segment revenue | 0 | 0 | |||||
| Revenue from operations | 1229364000 | ||||||
| 2 | Segment Result | ||||||
| Profit (+) / Loss (-) before tax and interest from each segment | |||||||
| 1 | Pharmaceuticals Drugs and Formulations | 196572000 | 196572000 | ||||
| 2 | Trading of Commodities | 135000 | 135000 | ||||
| 3 | Renting of Properties | 8312000 | 8312000 | ||||
| Total Profit before tax | 205019000 | ||||||
| i. Finance cost | 2508000 | 2508000 | |||||
| ii. Other Unallocable Expenditure net off Unallocable income | 0 | 0 | |||||
| Profit before tax | 202511000 | ||||||
| 3 | (Segment Asset - Segment Liabilities) | ||||||
| Segment Asset | |||||||
| 1 | Pharmaceuticals Drugs and Formulations | 3978077000 | 3978077000 | ||||
| 2 | Trading of Commodities | 25918000 | 25918000 | ||||
| 3 | Renting of Properties | 473344000 | 473344000 | ||||
| Total Segment Asset | 4477339000 | 4477339000 | |||||
| Un-allocable Assets | 0 | 0 | |||||
| Net Segment Asset | 4477339000 | 4477339000 | |||||
| 4 | Segment Liabilities | ||||||
| Segment Liabilities | |||||||
| 1 | Pharmaceuticals Drugs and Formulations | 843663000 | 843663000 | ||||
| 2 | Trading of Commodities | 836000 | 836000 | ||||
| 3 | Renting of Properties | 13336000 | 13336000 | ||||
| Total Segment Liabilities | 857835000 | 857835000 | |||||
| Un-allocable Liabilities | 0 | 0 | |||||
| Net Segment Liabilities | 857835000 | 857835000 | |||||
| Disclosure of notes on segments | Textual Information(2) | ||||||
Text Block |
|
|---|---|
| Textual Information(2) | tttt nNotesttttt nThe above results were reviewed by the Audit Committee and approved by the Board at its meeting held on 08 08 2025tttt nThese above results have been prepared in compliance with the Indian Accounting Standard referred to as Ind AS as notified prescribed under Section 133 of the Companies Act, 2013 read with Companies Indian Accounting Standards Rules 2015 as amended from time to timetttt nThe company is operating in 3 segments A Pharmaceuticals Drugs and Formulations B Trading of Commodities C Renting of Property particulars of segment wise results are given as required.tttt nAs required under Regulation 33 of SEBI LODR Regulations, 2015 the limited review by the Statutory Auditors have been completed for the quarter ended on 30th June 2025. The report does not have any impact on the above results and notes which needs explanationtttt nPrevious period figures have been regrouped reclassified wherever necessary to confirm to this period classification nThe Company currently have 3 three Wholly Owned Subsidiaries namely Synmex Pharma Pvt. Ltd Sante Biotech Pvt. Ltd. and Vincit Biotech International Pvt. Ltd.t |
Other Comprehensive Income |
|||
|---|---|---|---|
| Particulars | 3 months/ 6 months ended (dd-mm-yyyy) | Year to date figures for current period ended (dd-mm-yyyy) | |
| A | Date of start of reporting period | 01-Apr-2025 | |
| B | Date of end of reporting period | 30-Jun-2025 | |
| C | Whether results are audited or unaudited | Unaudited | |
| D | Nature of report standalone or consolidated | Consolidated | |
| Other comprehensive income [Abstract] | |||
| 1 | Amount of items that will not be reclassified to profit and loss | ||
| Total Amount of items that will not be reclassified to profit and loss | |||
| 2 | Income tax relating to items that will not be reclassified to profit or loss | 0 | |
| 3 | Amount of items that will be reclassified to profit and loss | ||
| 1 | Items that will be reclassified to profit or loss | 40384000 | 40384000 |
| Total Amount of items that will be reclassified to profit and loss | 40384000 | ||
| 4 | Income tax relating to items that will be reclassified to profit or loss | 0 | |
| 5 | Total Other comprehensive income | 40384000 | |
Details of Impact of Audit Qualification |
|
|---|---|
| Whether results are audited or unaudited | Unaudited |
| Declaration of unmodified opinion or statement on impact of audit qualification | Declaration of unmodified opinion |
| Auditor's opinion | |
| Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results | Yes |
| Sr No. | Audit firm's name | Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI | Certificate valid upto | ||
| 1 | Sanjay Mehta & Associates | Yes | 31-Mar-2027 | ||
|---|---|---|---|---|---|